Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Cross Asset Strategy

<ul><li>Historical challenges of neurosciences. The complexity of the central nervous system (CNS), which includes the brain and spinal cord, is unrivalled in the human anatomy, being made up of billions of interacting neurons and other cells.</li><li>More than 600 neurologic diseases and conditions have been identified.</li><li>Historically, progress in developing disease-modifying, let alone curative solutions for these disorders, has been stymied by incomplete understanding of the CNS, diagnostic challenges due to the lack of reliable biomarkers, the blood-brain barrier (BBB) obstacle, and the high rate of clinical drug development failure rates. </li></ul>

Historical challenges of neurosciences. The complexity of the central nervous system (CNS), which includes the brain and spinal cord, is unrivalled in the human anatomy, being made up of billions of interacting neurons and other cells.More than 600 neurologic diseases and conditions have been identified.Historically, progress in developing disease-modifying, let alone curative solutions for these disorders, has been stymied by incomplete understanding of the CNS, diagnostic challenges due to the lack of reliable biomarkers, the blood-brain barrier (BBB) obstacle, and the high rate of clinical drug development failure rates. 

The Neurosciences Comeback